25-NSE ·Filed Aug 7, 2026

SRZN

Surrozen, Inc./DE
NEUTRAL
Impact 3/10
Horizonimmediate Processed1mo ago SEC0001354457-26-000770
Actionable Insight • Neutral

The warrant delisting is purely administrative and carries no negative signal for common shareholders. The removal ends any potential further dilution from these warrants. Monitor for any subsequent corporate events (merger, bankruptcy, or going-private) but this filing alone is not a trading catalyst.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
SRZN ▼ -17.58% at T+20d
NEUTRAL call ✗ call lost -17.58% · α vs SPY -16.66% · entry $25.09 → $20.68
Next anchor: T+60d in 4w
Latest observation: T+36 +47.98% FF3 residual α
Entry anchored
Aug 7, 2026
via day open
T+1d
-0.16%
call -0.16% · α +0.16%
$25.05
settled 8w ago
T+5d
-5.22%
call -5.22% · α -5.17%
$23.78
settled 7w ago
T+20d
-17.58%
call -17.58% · α -16.66%
$20.68
settled 28d ago
T+60d
—
call — · α —
—
in 4w

Price Chart

Loading chart...

Executive Summary

Nasdaq filed a Form 25-NSE on August 7, 2026 to remove from listing and registration the Warrants expiring 8/10/2026 of Surrozen, Inc. The delisting is tied to the warrants’ scheduled expiration, confirming these securities are no longer trading on Nasdaq. This is a routine administrative removal for a matured security and has no direct impact on the common stock.

Key Facts

  • Security removed: Warrants expiring 8/10/2026
  • Regulatory basis: 17 CFR 240.12d2-2(a)(2) (matured, redeemed, or retired securities)
  • Filed by Nasdaq Stock Market LLC on 2026-08-07
  • Effectiveness date: 2026-08-07
  • Subject company: Surrozen, Inc./DE (CIK 0001815730)
  • Notable: No impact on common stock (SRZN) or company operations; warrants simply reached their scheduled expiration

Financial Impact

No direct financial impact on Surrozen's common equity or operations; warrants expiring 8/10/2026 are being delisted due to maturity, not distress.

dilutionwarrant overhang

Risk Factors

  • Low: Routine delisting for expired warrants — no material risk to common shares
  • Low: Filing does not address common stock listing status

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (SRZN) — Batch item 10001354457-26-000770
Document: 0001354457-26-000770-index-headers.html0001354457-26-000770
Document: 0001354457-26-000770-index.html0001354457-26-000770
Document: 0001354457-26-000770.txt0001354457-26-000770
25-NSE Filing (SRZN) — Batch item 50001354457-26-000770
Document: 0001354457-26-000770-index-headers.html0001354457-26-000770
Document: 0001354457-26-000770-index.html0001354457-26-000770
Document: 0001354457-26-000770.txt0001354457-26-000770
4 reports for SRZN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SRZN — sortable, filterable
TypeNow
Aug 7, 2026
7w ago
25-NSE
NEUTRAL ★ 3/10
$25.09 $20.68▼ −17.58%▼ −16.66%$29.65 (+18.17%)
May 4, 2026
21w ago
Insider Cluster
NEUTRAL ★ 2/10
$32.07 $24.71▼ −22.95%▼ −28.59%$29.65 (−7.55%)
Mar 23, 2026
27w ago
S-3
BEARISH ★ 7/10
$25.00 $33.03▼ −32.12%▼ −23.22%$29.65 (−18.60%)
Mar 23, 2026
27w ago
Press Release
MIXED ★ 6/10
$25.00 $33.03▲ +32.12%▲ +23.22%$29.65 (+18.60%)
Showing 4 of 4

US Market Status

Market Open — Closes in 3h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access